While PD-L1 expression is associated with increased tumor infiltrating lymphocytes (TILs) and sensitivity to PD-1/PD-L1 inhibitors in extracranial tumors, the level and association between these markers in lung cancer BrM is unknown. The gene discussed is PDCD1; the disease is lung carcinoma.